Edity Therapeutics and Aurigene Oncology to Advance a Novel Cell Therapy Program for Solid Tumors April 8, 2025
Tovecimig (CTX-009) Meets Primary Endpoint in Ph 2/3 Study in Patients with Biliary Tract Cancer April 8, 2025
FDA Clears IND Application for Ph 1 Trial of RB-164 for Hematologic and Solid Malignancies April 8, 2025
Imfinzi-based perioperative regimen approved in the EU for resectable NSCLC based on AEGEAN Ph 3 trial results April 8, 2025
Boehringer Ingelheim strengthens ADC portfolio with new NBE Therapeutics R&D center in Basel April 8, 2025
BORUZU, First Ready-to-Use Bortezomib Injection for Multiple Myeloma and Mantle Cell Lymphoma, launched April 8, 2025
Preliminary positive immune response data announced from Ph 3 clinical trial FLAMINGO-01 of GLSI-100 April 8, 2025
SON-1010 Demonstrates a Strong Safety Profile in Combination with Atezolizumab for Treatment of Platinum-Resistant Ovarian Cancer April 8, 2025
FDA clears IND application for ALX2004 for the treatment of EGFR-expressing solid tumors April 8, 2025
European Commission approves SC RYBREVANT (amivantamab) for the treatment of patients with advanced EGFR-mutated NSCLC April 8, 2025
Enhertu approved in the EU for patients with HR-positive, HER2-low or HER2-ultralow metastatic breast cancer following at least one endocrine therapy April 8, 2025
